European Biotechnology
Thematic Network Association

Letter for Special Issue on COVID-19

Dear Colleagues,
Warm wishes from The EuroBiotech Journal

The Coronavirus Disease-2019 (COVID-19) had arisen with the quick spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Upon this quick rise in the number of affected individuals worldwide, World Health Organization (WHO) announced the pandemic of COVID-19 on March 11th, 2020. The manifestation of COVID-19 affected individuals changes from mild to critical conditions. Furthermore, a number of SARS-CoV-2 affected patients manifest the disease asymptomatic, whereas the most common symptoms are dry cough, fever and in some cases bilateral pneumonia. More than 103 million COVID-19 cases with one million deaths had been reported by January, 2020. Unfortunately, the spreading of the SARS-CoV-2 is rising and the impact of the transmission is still growing.

Detailed investigations together with international parties are essential to better understanding the viral dynamics, to identify new diagnostic approaches as well as to developed possible therapeutic agents.

As the rising journal of Biotechnology, The EBTJ will publish the special issue about COVID-19 aiming to publish scientific evidence, findings and observations related the pandemic. We are honored to request you to contribute our journals special issue with your valuable work. We welcome the submission of original research articles, reviews, mini reviews, case reports, editorial and brief reports.

Dr. Raheleh Rahbari (Wellcome Trust Sanger Institute)
Dr. Pierpaolo Maisano Delser (University of Cambridge)
Assoc. Prof. Mahmut Cerkez Ergoren (Near East University)
Guest Editors


  • SARS-CoV-2
  • COVID-19
  • Molecular Diagnostics
  • Therapeutic options
  • Viral variants
  • Epidemiology

Manuscript submission information:

Manuscript should be submitted online at:$002febtj$002febtj-overview.xml?tab_body=editorialContent-79129.

Once you are registered, manuscript can be submitted until 1 May 2021. All papers will be peer-reviewed. Submitted manuscripts should not have been published previously, nor ne under consideration for another journal (except conference/congress proceeding papers).
Hopefully looking forward for your participation.

The Eurobiotech Journal
Editorial Board